Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 7/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PRF1 | P14222 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419922 | 0.87 | GRM5 (0.42) | PGRGRM5CYP2C19POLBALDH1A1 | |
| SCHEMBL13824745 | 0.87 | CYP2C19 (0.47) | GRM5CYP2C19ALDH1A1HTT | |
| SCHEMBL4421767 | 0.86 | CYP2C19 (0.45) | PGRGRM5CYP2C19ALDH1A1HTT | |
| SCHEMBL4423877 | 0.86 | WRN (0.45) | GRM5CYP2C19ALDH1A1HTT | |
| SCHEMBL4426647 | 0.85 | PGR (0.45) | PGRGRM5CYP2C19POLBALDH1A1 | |
| SCHEMBL4429683 | 0.85 | HSD17B1 (0.50) | GRM5CYP2C19PRF1ALDH1A1HTT | |
| SCHEMBL4425797 | 0.85 | CYP2C19 (0.42) | GRM5CYP2C19ALDH1A1HTT | |
| SCHEMBL8283632 | 0.85 | PGR (0.58) | PGRGRM5BACE1CYP2C19POLB | |
| SCHEMBL4422371 | 0.84 | MAP4K1 (0.43) | CYP2C19ALDH1A1HTT | |
| SCHEMBL4432531 | 0.83 | GRM5 (0.49) | PGRGRM5BACE1BACE2PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | claimed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | claimed |
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | claimed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | claimed |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | claimed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | claimed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | claimed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | PGR 2250/4885GRM5 2/4885BACE1 2237/4885 |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | PGR 2900/4885GRM5 1/4885BACE1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.